Is BRISTOL MYERS SQUIBB CO (BMY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 38.4% / 30% | 8.7% / 30% | 11.8% / 30% | 5.2% / 5% | ✗ NOT HALAL |
| DJIM | 38.4% / 33% | 8.7% / 33% | 11.8% / 33% | 5.2% / 5% | ✗ NOT HALAL |
| MSCI | 52.4% / 33% | 11.9% / 33% | 16.1% / 33% | 5.2% / 5% | ✗ NOT HALAL |
| S&P | 38.4% / 33% | 8.7% / 33% | 11.8% / 33% | 5.2% / 5% | ✗ NOT HALAL |
| FTSE | 52.4% / 33% | 11.9% / 33% | 16.1% / 50% | 5.2% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 72.6% | |
| Operating Margin | 28.2% | |
| Net Margin | 14.6% | |
| Return on Equity (ROE) | 40.4% | |
| Return on Assets (ROA) | 10.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $14.2B |
| Free Cash Flow | $12.8B |
| Total Debt | $47.1B |
| Debt-to-Equity | 255.0 |
| Current Ratio | 1.3 |
| Total Assets | $90.0B |
Price & Trading
| Last Close | $59.43 |
| 50-Day MA | $58.75 |
| 200-Day MA | $50.62 |
| Avg Volume | 13.5M |
| Beta | 0.3 |
|
52-Week Range
$42.52
| |
About BRISTOL MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BRISTOL MYERS SQUIBB CO (BMY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BRISTOL MYERS SQUIBB CO is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BRISTOL MYERS SQUIBB CO's debt ratio?
BRISTOL MYERS SQUIBB CO's debt ratio is 38.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 52.4%.
What are BRISTOL MYERS SQUIBB CO's key financial metrics?
BRISTOL MYERS SQUIBB CO has a market capitalization of $119.5B, trailing P/E ratio of 16.9, and revenue of $48.2B. The company maintains a gross margin of 72.6% and a net margin of 14.6%. Return on equity stands at 40.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.